Prognostic and predictive value of thymidylate synthase expression in colon cancer

Digestive Diseases and Sciences

Volumn 53, Issue 5, 2008, Pages 1289-1296

  Tsourouflis, Gerasimos ^a   Theocharis, Stamatios E ^a   Sampani, Anastasia ^a   Giagini, Athina ^a   Kostakis, Alkiviadis ^a   Kouraklis, Gregory ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Cell cycle related molecules; Colon cancer; Thymidylate synthase

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN D1; CYCLIN E; FLUOROURACIL; KI 67 ANTIGEN; PROTEIN P16; PROTEIN P21; RETINOBLASTOMA PROTEIN; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SURVIVAL; CELL CYCLE; CELL PROLIFERATION; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; COLON CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DNA SYNTHESIS; ENZYME INHIBITION; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARAMETER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; COLONIC NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL RATE; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL;

EID: 41949102825     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-007-0008-x     Document Type: Article

References (40)

1. Johnston PG, Allegra CJ (1995) Colorectal cancer biology: clinical implications. Semin Oncol 22:418-432
2. Johnston PG, Benson AB III, Catalano P, Rao MS, O'Dwyer PJ, Allegra CJ (2003) Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. J Clin Oncol 21:815-819
3. Mamounas E, Wieand S, Wolmark N, Bear HD, Atkins JN, Song K, Jones J, Rockette H (1999) Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: result from four National surgical adjuvant breast and bowel project adjuvant studies C-01, C-02, C-03, & C-04). J Clin Oncol 17:1349-1355
4. Popat S, Matakidou A, Houlston R (2004) Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 22:529-536
5. Danenberg PV, Heidelberger C, Mulkins MA, Peterson AR (1981) The incorporation of 5-fluoro-2′-deoxyuridine into DNA of mammalian tumor cells. Biochem Biophys Res Commun 102:654-658
6. Carreras CW, Santi DV (1995) The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem 64:721-762
7. Johnston PG, Drake JC, Trepel J, Allegra CL (1992) Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil sensitive and resistant human cancer cell lines. Cancer Res 52:4306-4312
8. Drake JC, Allegra CJ, Moran RG, Johnston PG (1996) Resistance to Tomudex (ZD1694): multifactorial in human breast and colon carcinoma cell lines. Biochem Pharmacol 51:1349-1355
9. Wolmark N, Rockette H, Mamounas E, Jones J, Wieand S, Wickerham DL, Bear HD, Atkins JA, Dimitrov NV, Glass AG, Fisher ER, Fisher B (1999) Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17:3553-3559
10. Haller DG, Catalano PJ, Macdonald JS, Mayer RJ (1998) Fluorouracil, leucovorin and levamisole adjuvant therapy for colon cancer: five-year final report of INT-0089. Proc Am Soc Clin Oncol 17:256a
11. Chu E, Callender MA, Farrell MP, Schmitz JC (2003) Thymidylate synthase inhibitors as anticancer agents: from bench to bedside. Cancer Chemother Pharmacol 52:S80-S89
12. Tomiak A, Vincent M, Earle CC, Johnston PG, Kocha W, Taylor M, Maroun J, Eidus L, Whiston F, Stitt L (2001) Thymidylate synthase expression in stage II and III colon cancer: a retrospective review. Am J Clin Oncol 24:597-602
13. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322-1327
14. Paradiso A, Simone G, Petroni S, Leone B, Vallejo C, Lacava J, Romero A, Machiavelli M, De Lena M, Allegra CJ, Johnston PG (2000) Thymidylate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 82:560-567
15. Sakamoto J, Hamashima H, Susuki H, Ito K, Mai M, Saji S, Fukushima M, Matsushita Y, Nakazato H (2003) Thymidylate synthase expression as a predictor of the prognosis of curatively resected colon carcinoma in patients registered in an adjuvant immunochemotherapy clinical trial. Oncl Rep 10:1081-1090
16. Edler D, Hallstrom M, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H (2000) Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. Clin Cancer Res 6:1378-1384
17. Edler D, Kressner U, Ragnhammar P, Johnston PG, Magnusson I, Glimelius B, Påhlman L, Lindmark G, Blomgren H (2000) Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival. Clin Cancer Res 6:488-492
18. Lenz HJ, Danenberg KD, Leichman CG, Florentine B, Johnston PG, Groshen S, Zhou L, Xiong YP, Danenberg PV, Leichman LP (1998) p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. Clin Cancer Res 4:1227-1234
19. Sakamoto J, Fukushima M, Hamashima H (1999) Thymidylate synthase expression predict prognosis of curatively resected colorectal carcinoma patients registered in an adjuvant immunochemotherapy clinical trial. Proc ASCO 18:268a
20. Sanguedolce R, Vultaggio G, Sanguedolce F, Modica G, Li Volsi F, Diana G, Guereio G, Bellanca L, Rausa L (1998) The role of thymidylate synthase levels in the prognosis and the treatment of patients with colorectal cancer. Anticancer Res 18:1515-1520
21. Goldberg RM, Sargent D, Mahoney MR (1998) Limited prognostic importance of immunohistochemical parameters (IHP) [thymidylate synthase (TS), KI-67, and P53] in 465 patients with Dukes' B2 and C colon cancer enrolled on North Central Cancer Treatment Group (NCCTG) trials. Proc ASCO 18:267a
22. Elwell A, Xiong YP, Chang M (1997) p53, p21 and thymidylate synthase protein expression: associations with recurrence in stage II and III rectal cancer. Proc ASCO 16:258a
23. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA, Allegra CJ (1994) The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12:2640-2647
24. Edler D, Blomgren H, Allegra CJ, Johnston PG, Lagerstedt U, Magnusson I, Ragnhammar P (1997) Immunohistochemical determination of thymidylate synthase in colorectal cancer-methodological studies. Eur J Cancer 33:2278-2281
25. Lichtenstein E (1997) Behavioral research contributions and needs in cancer prevention and control: Tobacco use prevention and cessation. Prev Med 26:S57-S63
26. Sherr CJ (1994) G1 phase progression: cycling on cue. Cell 79:551-555
27. Meyerson M, Harlow E (1994) Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol 14:2077-2086
28. Dulic V, Lees E et al (1992) Association of human cyclin E with a periodic G1-S phase protein kinase. Science 257:1958-1961
29. Elledge SJ, Richman R, Hall FL, Williams RT, Lodgson N, Harper JW (1992) Cdk2 encodes a 33-kDa cyclin A-associated protein kinase and is expressed before Cdc2 in the cell cycle. Proc Natl Acad Sci USA 89:2907-2911
30. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M (1995) Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 15:2612-2624
31. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704
32. Longley DB, Ferguson PR, Boyer J, Latif T, Lynch M, Maxwell P, Harkin DP, Johnston PG (2001) Characterization of a thymidylate synthase (TS)-inducible cell line. Clin Cancer Res 7:3533-3539
33. Yin MB, Guo B, Panadero A, Frank C, Wrzosek C, Slocum HK, Rustum YM (1999) Cyclin E-Cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex. Exp Cell Res 247:189-199
34. 16INK4a-mediated cellular arrest as an indicator of chemosensitivity to 5-fluorouracil. Pathol Int 54:564-575
35. INK4a in advanced colorectal cancer: implication of TS expression in 5-FU-based adjuvant chemotherapy. Jpn J Clin Oncol 34:594-601
36. INK4A contributes to the outcome of cancer therapy. Cell 109:335-346
37. Omura K, Uno Y, Kawakami K, Kanehira E, Tawaraya K, Tsukayama M, Hiranuma C, Watanabe Y (2000) Expression of thymidylate synthase in human gastric and colorectal adenocarcinomas is upregulated by p16/INK4. Hepatogastroenterology 47:742-745
38. Backus HHJ, van Groeningen CJ, Vos W, Dukers DF, Bloemena E, Wouters D, Pinedo HM, Reters GJ (2002) Differential expression of cell cycle and apoptosis related proteins in colorectal mucosa, primary colon tumours, and liver metastases. J Clin Pathol 55:206-211
39. Backus HH, van Riel JM, van Groeningen CJ, Vos W, Dukers DF, Bloemena E, Wouters D, Pinedo HM, Reters GJ (2001) Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer. Ann Oncol 12:779-785
40. Hayes DF, Bast RC, Desch CE, Fritsche H, Kemeny NE Jr., Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S, Winn RJ (1996) Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88:1456-1466